Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia

European Journal of Clinical Pharmacology

Volumn 67, Issue 5, 2011, Pages 471-476

  Holstein, Andreas ^a   Hahn, Michael ^a   Patzer, Olaf ^a   Seeringer, Angela ^b   Kovacs, Peter ^c   Stingl, Julia ^b  

^a KLINIKUM LIPPE DETMOLD   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

CYP2C9 variants; Hypoglycemia; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLIMEPIRIDE; GLIQUIDONE; GLUCOSE; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE;

AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR;

AGED; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOMIC STRUCTURAL VARIATION; GENOTYPE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 79955656953     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0976-1     Document Type: Article

References (22)

1. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
3. ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572 (Pubitemid 351831357)
4. Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481-489
5. Amiel SA, Dixon T, Mann R et al (2008) Hypoglycaemia in type 2 diabetes. Diab Med 25:245-254 (Pubitemid 351322690)
6. Holstein A, Hammer C, Hahn M et al (2010) Severe sulphonylurea-induced hypoglycaemia - a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 9:675-681
7. Kirchheiner J, Bauer S, Meineke I et al (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109 (Pubitemid 34298914)
8. Kirchheiner J, Brockmöller J, Meiniki L et al (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296 (Pubitemid 34311458)
9. Niemi M, Cascorbi I, Timm R et al (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72:326-332
10. Becker ML, Visser LE, Trienekens PH et al (2008) Cytochrome P450 2 C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 83:288-292
11. Ragia G, Petridis I, Tavridou A et al (2009) Presence of CYP2C9*3 allele increases risk for hypoglycaemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10:1781-1787
12. Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmöller J, Kirchheiner J (2005) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60:103-106 (Pubitemid 40942788)
13. Holstein A, Plaschke A, Vogel M-Y et al (2003) Prehospital management of diabetic emergencies - a population-based intervention study. Acta Anaesthesiol Scand 47:610-615 (Pubitemid 36539508)
14. Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
15. Wang R, Chen K, Wen SY et al (2005) Pharmacokinetics of glimepiride and cytochrome P450 2 C9 genetic polymorphisms. Clin Pharmacol Ther 78:90-92 (Pubitemid 40956936)
16. Suzuki K, Yanagawa T, Shibasaki T et al (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diab Res Clin Pract 72:148-154
17. Zhou K, Donnelly N, Burch L et al (2010) Loss of function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 87:52-56
18. American Diabetes Association (ADA) Workgroup on Hypoglycaemia (2005) Defining and reporting hypoglycaemia in diabetes. Diab Care 28:1245-1249
19. Leese GP, Wang J, Broomhall J et al (2003) Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diab Care 26:1176-1180
20. Asplund K, Wiholm B-E, Lithner F (1983) Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24:412-417
21. Greco D, Oisciotta M, Gambina F et al (2010) Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diab 118:215-219
22. Holstein A, Hahn M, Stumvoll M et al (2009) The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 41:387-390